CRTX:

p9.50

UNCH

Crism Therapeutics Corporation

GBX as of Aug 3, 2026 | LSE - London Stock Exchange

Company Profile FTSE AIM All-Share

1-Year Price Evolution & Moving Averages

1-Year: -11.63%

Multi-timeframe price chart with technical indicators - Penny sterling (GBX)

Company Description

Company Profile

Crism Therapeutics Corporation is a clinical-stage biopharmaceutical company focused on discovering and developing innovative gene-based medicines. The company's primary function is to harness the potential of a proprietary technology platform to create transformative therapies for serious diseases. Crism Therapeutics targets key areas such as genetic disorders, hemophilia, and other hematologic conditions, aiming to improve patient outcomes through precision medicine. The asset has a significant presence in the biotechnology sector, impacting areas of health technology and pharmaceuticals. As a pioneer in gene editing techniques, Crism Therapeutics plays a crucial role in advancing scientific research and development within the medical community. Its commitment to innovation makes it a critical player in the broader market, driving innovation and expanding treatment possibilities in clinically unmet needs.

Healthcare Biotechnology

Risk & Valuation

as of Jul. 21, 2026

Beta	0.60
Trailing PE	0.03
Forward PE

Stock Data

Open	p9.50
High	p10.00
Low	p9.17
Close	p9.50
Volume	254,163
Previous Close	p9.50
1-Day Change	0.00
1-Year Change	-1.25
Average Daily Volume	196,555
52-Week High	p17.50
52-Week Low	p8.38

Disclaimer

All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!

Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.

Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.

Please conduct your own due diligence to verify insights.